Full Press Release Details
DUBLIN,Nov. 19, 2025/PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) today announced that management will participate in the following investor conferences in December 2025:
8thAnnual Evercore Healthcare ConferenceLocation: Coral Gables, FLFormat: Fireside ChatDate: Thursday, December 4, 2025Time: 8:20-8:40 AM ETWebcast
Oppenheimer Movers in Rare Disease SummitLocation: New York, NYFormat: Panel Discussion - Elevator Pitches from Rare Disease Companies with Key Near-Term, Potentially Stock-Moving CatalystsDate: Thursday, December 11, 2025Time: 2:15-2:45 PM ET
Theravance will be available for one-on-one meetings during both events. Interested investors should contact their respective representatives to request meetings.
A live webcast of the Evercore presentation may also be accessed on the "Events and Presentation" page under the Investors section onTheravance.com. A replay of the webcast will be archived on the Company's website for 30 days.
About Theravance BiopharmaTheravance Biopharma, Inc.'s focus is to deliverMedicines that Make a Difference®in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI®(revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.
For more information, please visitwww.theravance.com.THERAVANCE BIOPHARMA®, THERAVANCE®and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).
YUPELRI®is a registered trademark of Viatris Specialty LLC. Trademarks, trade names or service marks of other companies appearing on this press release are the property of their respective owners.